Bluejay Diagnostics Company Insiders
| BJDX Stock | USD 1.57 0.04 2.48% |
Bluejay Diagnostics employs about 7 people. The company is managed by 11 executives with a total tenure of roughly 17 years, averaging almost 1.0 years of service per executive, having 0.64 employees per reported executive. Break down of Bluejay Diagnostics' management performance can provide insight into the company performance.
Bluejay Diagnostics Management Team Effectiveness
The company has return on total asset (ROA) of (0.8005) % which means that it has lost $0.8005 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0056) %, meaning that it created substantial loss on money invested by shareholders. Bluejay Diagnostics' management efficiency ratios could be used to measure how well Bluejay Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.22 in 2025. Return On Capital Employed is likely to drop to -1.29 in 2025. At this time, Bluejay Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 37 K in 2025, whereas Net Tangible Assets are likely to drop slightly above 6.8 M in 2025.Common Stock Shares Outstanding is likely to drop to about 134 K in 2025. Net Loss is likely to rise to about (7.9 M) in 2025
Bluejay Diagnostics Workforce Comparison
Bluejay Diagnostics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 166. Bluejay Diagnostics holds roughly 7.0 in number of employees claiming about 4% of equities under Health Care industry.
Bluejay Diagnostics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bluejay Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bluejay Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bluejay Diagnostics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zeidman Fred S over three months ago Acquisition by Zeidman Fred S of 27500 shares of Bluejay Diagnostics at 0.44 subject to Rule 16b-3 | ||
Gemignani Gary G over three months ago Acquisition by Gemignani Gary G of 25000 shares of Bluejay Diagnostics at 2.72 subject to Rule 16b-3 | ||
Gemignani Gary G over six months ago Acquisition by Gemignani Gary G of 2500 shares of Bluejay Diagnostics subject to Rule 16b-3 | ||
Dey Svetlana over six months ago Acquisition by Dey Svetlana of 10000 shares of Bluejay Diagnostics at 0.44 subject to Rule 16b-3 | ||
Jason Cook over six months ago Disposition of 5324 shares by Jason Cook of Bluejay Diagnostics at 1.09 subject to Rule 16b-3 | ||
Zeidman Fred S over six months ago Acquisition by Zeidman Fred S of 2500 shares of Bluejay Diagnostics subject to Rule 16b-3 | ||
Zeidman Fred S over a year ago Acquisition by Zeidman Fred S of 2500 shares of Bluejay Diagnostics subject to Rule 16b-3 | ||
Indranil Dey over a year ago Purchase by Indranil Dey of 500 shares of Bluejay Diagnostics |
Bluejay Diagnostics Notable Stakeholders
A Bluejay Diagnostics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bluejay Diagnostics often face trade-offs trying to please all of them. Bluejay Diagnostics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bluejay Diagnostics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Frances Scally | Principal CFO | Profile | |
| Kenneth CPA | Chief Officer | Profile | |
| Mr MD | Chief Advisor | Profile | |
| Kevin Vance | Chief Officer | Profile | |
| Jason Cook | Chief Officer | Profile | |
| Mark MD | Chief Advisor | Profile | |
| Les DeLuca | Vice Operations | Profile | |
| Eryn Graham | Marketing Manager | Profile | |
| Ryan McSeveney | Corporate Controller | Profile | |
| Mark Feinberg | Chief Advisor | Profile | |
| Indranil Dey | Accounting Financial | Profile |
About Bluejay Diagnostics Management Performance
The success or failure of an entity such as Bluejay Diagnostics often depends on how effective the management is. Bluejay Diagnostics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bluejay management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bluejay management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.16) | (1.22) | |
| Return On Capital Employed | (1.23) | (1.29) | |
| Return On Assets | (1.16) | (1.22) | |
| Return On Equity | (1.35) | (1.41) |
Please note, the imprecision that can be found in Bluejay Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bluejay Diagnostics. Check Bluejay Diagnostics' Beneish M Score to see the likelihood of Bluejay Diagnostics' management manipulating its earnings.
Bluejay Diagnostics Workforce Analysis
Traditionally, organizations such as Bluejay Diagnostics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bluejay Diagnostics within its industry.Bluejay Diagnostics Manpower Efficiency
Return on Bluejay Diagnostics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 701.6K | |
| Working Capital Per Employee | 584.1K | |
| Working Capital Per Executive | 371.7K |
Additional Tools for Bluejay Stock Analysis
When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.